title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma

summary: This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

ipd_sharing_description:
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

lead_sponsor: Acerta Pharma BV

location_country:
Peru
Greece
Romania
Belgium
Australia
Russian Federation
Ukraine
France
Japan
Poland
Argentina
Canada
Korea, Republic of
Hong Kong
Vietnam
Hungary
China
Germany
United States
Italy
Brazil
Czechia
Israel
Spain


type: EudraCT Number

title: A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

summary: The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.

study_start_date_type: Actual

status: Recruiting

study_completion_date_type: Anticipated

study_type: Interventional

design_allocation: Non-Randomized

primary_purpose: Treatment

enrollment_type: Anticipated

ipd_sharing: Yes

ipd_sharing_description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.

lead_sponsor: Astellas Pharma Global Development, Inc.

location_country:
Finland
Belgium
Australia
Russian Federation
Denmark
France
Poland
Slovakia
Argentina
Moldova, Republic of
Canada
Korea, Republic of
South Africa
Chile
Sweden
United States
Germany
United Kingdom
Italy
Czechia
Israel
Georgia
New Zealand
Spain

location_facility:
Site BE32004
Site AU61001
Site GB44004
Site DK45001
Site US10062
Site SK10223
Site US10055
Site US10031
Site US10023
Site BE32002
Site IL97202
Site US10017
Site CZ42003
Site ES34005
Site US10027
Site IL97203
Site KR82002
Site US10015
Site AU61004
Site US10043
Site US10038
Site US10018
Site FR33004
Site AU61006
Site IT39005
Site PL48001
Site CZ42002
Site US10020
Site FR33017
Site US10035
Site BE32001
Site BE32005
Site FR33008
Site DK45004
Site US10052
Site SE46003
Site FR33010
Site AU61009
Site GE99501
Site KR82001
Site DE49006
Site DE49013
Site DK45002
Site GB44007
Site US10030
Site CL56001
Site US10046
Site CZ42001
Site IT39001
Site NZ64001
Site US10002
Site DE49004
Site US10050
Site DE49003
Site FR33006
Site BE32003
Site DK45003
Site IT39002
Site ES34004
Site US10040
Site US10048
Site KR82003
Site RU70001
Site GB44008
Site US10053
Site CL56004
Site US10001
Site GB44006
Site FR33002
Site FR33001
Site US10028
Site DE49010
Site US10029
Site ZA27001
Site MD37301
Site DE49007
Site ES34003
Site US10049
Site US10022
Site AU61008
Site GB44002
Site AR54003
Site ES34001
Site CA15011
Site FR33003
Site US10009
Site US10042
Site RU70003
Site KR82005
Site PL48003
Site GB44001
Site US10011
Site CA15003
Site BE32008
Site SE46001
Site US10010
Site CL56002
Site KR82004
Site PL48004
Site US10059
Site US10008
Site US10034
Site US10003
Site US10014
Site IT39004
Site CA15001
Site US10032
Site US10007
Site GB44003
Site GB44005
Site PL48002
Site FL35802
Site US10041
Site DE49001
Site BE32007
Site US10024
Site GB44009
Site AR54002
Site US10005
Site US10004
Site US10021
Site IL97204

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Ongoing


design_allocation: Randomized

status: Terminated

lead_sponsor: Eisai Co., Ltd.

enrollment_type: Actual

location_country:
Austria
Spain
Germany
France
Bulgaria
Czechia
Greece
Japan
Korea, Republic of
Poland
Argentina
Australia
Russian Federation
Portugal
Slovakia
United States
United Kingdom
Canada

location_facility:
Facility #8
Facility #4
Eisai Trial Site 3
Facility #2
Facility #5
Facility #1
Eisai Trial site 2
Facility #9
Facility #6
Eisai Trial Site 1
Facility #10
Facility #11
Facility #3
Eisai Trial site 5
Eisai Trial Site 4
Eisai Trail Site 1
Facility #7
Eisai Trial Site 2

ipd_sharing: Undecided

study_completion_date_type: Actual

source: euctr

title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

summary: The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.

status_simplified: Unknown


title: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adult Subjects

summary: The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in HIV-1 infected participants.

status: Completed

ReferenceType: background

ReferenceCitation: A Gori, G Rizzardini, C Miralles, J Olalla, JM Molina, F Raffi, P Kumar, A Antinori, M Ramgopal, HJ Stellbrink, M Das, H Chu, R Ram, W Garner, SK Chuck, D Piontkowsky, R Haubrich. Switching from An Abacavir (ABC)/Lamivudine (3TC)-Based Regimen to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) is Efficacious and Safe: Week 24 Primary Analysis of a Randomized Controlled Study in Virologically-Suppressed Adults [Presentation]. XVIII Congrès National de la SFLS, 19-20 October 2017, Nice Acropolis, France

ipd_sharing_description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

lead_sponsor: Gilead Sciences

location_country:
Italy
United States
France
Spain
Germany
United Kingdom

location_facility: Azienda Ospedaliero Universitaria Policlinico di Modena

location_facility: Unità Operativa Complessa di Malattie Infettive

location_facility: Hospital Clínico Universitario de Valencia (Galindo)

location_facility: The Positive Health Clinic, Allegheny Health Network

location_facility: AIDS Arms, Inc./Trinity Health & Wellness Center

location_facility: Steinhart Medical Associates dba The Kinder Medical Group

location_facility: Dipartimento di Malattie Infettive e Tropicali

location_facility: Hospital General Universitario de Valencia (Abril)

location_facility: Hospital General Universitario Gregorio Maranon

location_facility: Midway Immunology & Research Center, LLC

location_facility: Comprensorio Ospedaliero Amedeo di Savoia

location_facility: Unit Infectious Diseases - University of Catania - ARNAS Garibaldi

location_facility: Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.

status_simplified: Completed


title: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants

summary: The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, anti-retroviral therapy (ART)-naïve adult participants. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4 weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B*5701 positive at Screening may enroll into the study and receive DTG plus a non-abacavir containing dual nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week [-20] to Day 1). Participants who have an HIV 1 ribose nucleic acid (RNA) <50 copies per milliliter (c/mL) at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from visit Week 4b until study completion or withdrawal. Participants who successfully complete Week 100 (without meeting study defined withdrawal criteria and who remain virologically suppressed through Week 96: HIV-1 RNA <50 c/mL) will be given the option to switch to the LA arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn from the study. Participants will continue to receive injections every 4 weeks during the Extension Phase until CAB LA and RPV LA are either locally approved and commercially available, the participant no longer derives clinical benefit, the participant meets a protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA is terminated.

status: Active, not recruiting

ReferenceCitation: Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4.

ReferenceType: derived

ReferenceCitation: Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, DeMoor R, Griffith S, Thiagarajah S, Van Solingen-Ristea R, Ford SL, Crauwels H, Patel P, Cutrell A, Smith KY, Vandermeulen K, Birmingham E, St Clair M, Spreen WR, D'Amico R. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14.

family: Orkin

full_name: Chloe Orkin

given: Chloe

sequence: first

family: Bernal Morell

full_name: Enrique Bernal Morell

given: Enrique

sequence: additional

family: Tan

full_name: Darrell H S Tan

given: Darrell H S

family: Katner

full_name: Harold Katner

given: Harold

family: Stellbrink

full_name: Hans-Jürgen Stellbrink

given: Hans-Jürgen

family: Belonosova

full_name: Elena Belonosova

given: Elena

family: DeMoor

full_name: Rebecca DeMoor

given: Rebecca

family: Griffith

full_name: Sandy Griffith

given: Sandy

family: Thiagarajah

full_name: Shanker Thiagarajah

given: Shanker

family: Van Solingen-Ristea

full_name: Rodica Van Solingen-Ristea

given: Rodica

family: Ford

full_name: Susan L Ford

given: Susan L

family: Crauwels

full_name: Herta Crauwels

given: Herta

family: Patel

full_name: Parul Patel

given: Parul

family: Cutrell

full_name: Amy Cutrell

given: Amy

family: Smith

full_name: Kimberly Y Smith

given: Kimberly Y

family: Vandermeulen

full_name: Kati Vandermeulen

given: Kati

family: Birmingham

full_name: Eileen Birmingham

given: Eileen

family: St Clair

full_name: Marty St Clair

given: Marty

family: Spreen

full_name: William R Spreen

given: William R

family: D'Amico

full_name: Ronald D'Amico

given: Ronald

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: The Lancet HIV

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

ReferenceCitation: Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG, Morell EB, Tan DHS, D'Amico R, Dorey D, Griffith S, Thiagarajah S, St Clair M, Van Solingen-Ristea R, Crauwels H, Ford SL, Patel P, Chounta V, Vanveggel S, Cutrell A, Van Eygen V, Vandermeulen K, Margolis DA, Smith KY, Spreen WR. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4. Erratum in: Lancet HIV. 2021 Aug 12;:.

ReferenceCitation: Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masiá M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466.

journal_name: JAIDS Journal of Acquired Immune Deficiency Syndromes

repository_institution: Queen Mary University of London - Queen Mary Research Online

repository_institution: Universidad Autónoma de Madrid - Biblos-e Archivo

publisher: Ovid Technologies (Wolters Kluwer Health)

ipd_sharing_description: IPD for this study will be made available via the Clinical Study Data Request site.

location_country:
Italy
United States
South Africa
Netherlands
France
Japan
Russian Federation
Spain
Germany
United Kingdom
Canada


intervention_type: Biological

ipd_sharing_description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

lead_sponsor: Baxalta now part of Shire

location_country:
Italy
Austria
Netherlands
Germany
France
Czechia
Belgium
Russian Federation
Spain
Turkey
United States
United Kingdom
Ukraine

acronym:
BAX 111 rVWF in Pediatrics

 BAX 111 rVWF dans la population pédiatrique

location_facility: Comprehensive Cancer Center of Wake Forest Unversity

location_facility: Azienda Ospedaliera Pediatrica Santobono Pausillipon

location_facility: University of Colorado Hemophilia & Thrombosis Center

location_facility: Bleeding and Clotting Disorders Institute

location_facility: Groupement Hospitalier Est- Hôpital Louis Pradel

location_facility: SBEI HPE Altai State Medical University of MoH and SD

location_facility: University of Florida College of Medicine

location_facility: FSBI of Science "Kirov Scientific and Research Institute of Hematology and Blood Transfusion of FMBA

location_facility: Groupe Hospitalier Pellegrin - Hôpital Pellegrin

location_facility: Azienda Ospedaliera Universitaria Careggi

location_facility: Istanbul University Cerrahpasa Medical Faculty

location_facility: Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

location_facility: St. Jude Affiliate Clinic at Novant Health

location_facility: Texas Children's Cancer and Hematology Center

location_facility: Cincinnati Children's Hospital Medical Center

location_facility: Hospital Universitari i Politecnic La Fe

location_facility: Groupement Hospitalier Sud - Hôpital Bicêtre

location_facility: Hospital General Universitario de Alicante

location_facility: Indiana Hemophilia and Thrombosis Center

location_facility: SAIH "Kemerovo Regional Clinical Hospital"

location_facility: SI Institute of Blood Pathology and Transfusion Medicine of NAMSU

location_facility: Comprehensive Center for Bleeding Disorders

title: A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease

summary:
The purpose of this study in pediatric participants (<18 years of age) with severe hereditary von Willebrand disease (VWD) is:

To assess the efficacy, safety, and tolerability of recombinant von Willebrand Factor (rVWF), with or without ADVATE, in the treatment and control of nonsurgical bleeding events
To assess the efficacy and safety of rVWF with ADVATE during elective or emergency surgery
To determine the pharmacokinetic (PK) profile of rVWF


title: A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

summary: This 6-month extension study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) in subjects with Dementia with Lewy bodies (DLB) who have participated in the double-blind, placebo-controlled, lead-in study RVT-101-2001.

lead_sponsor: Axovant Sciences Ltd.

location_country:
Italy
Netherlands
France
Spain
United States
United Kingdom
Canada


title: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents

summary: A Phase 3, randomized, open-label, parallel-group, multicenter study designed to evaluate the efficacy and safety of guadecitabine in subjects with MDS or CMML who failed or relapsed after adequate prior treatment with azacitidine, decitabine, or both. This global study will be conducted in approximately 15 countries. Approximately 408 subjects from approximately 100 study centers will be randomly assigned in a 2:1 ratio to either guadecitabine (approximately 272 subjects) or Treatment Choice (approximately 136 subjects). The study consists of a 14-day screening period, a treatment period, a safety follow-up visit, and a long-term follow-up period. The study is expected to last more than 2 years, and the duration of individual subject participation will vary. Subjects may continue to receive treatment for as long as they continue to benefit.

ipd_sharing: No

lead_sponsor: Astex Pharmaceuticals, Inc.

location_country:
Italy
United States
Sweden
Germany
France
Czechia
Japan
Poland
Belgium
Spain
Denmark
Canada
United Kingdom
Korea, Republic of

location_facility: Centre Hospitalier Universitaire de Toulouse

location_facility: Azienda Ospedaliero Universitaria Careggi

location_facility: Chelsea and Westminster Hospital NHS Foundation Trust

location_facility: University of Texas MD Anderson Cancer Center

location_facility: Hospital General Universitario Gregorio Marañon

location_facility: Ziekenhuis Netwerk Antwerpen Stuivenberg

location_facility: Azienda Ospedaliera Universitaria San Martino

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Samodzielny Publiczny Centralny Szpital Kliniczny

location_facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

location_facility: Azienda Ospedaliera Ospedali Riuniti Marche Nord

location_facility: Azienda Ospedaliera Universitaria-Maggiore della Carità di Novara

location_facility: Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria

location_facility: Maisonneuve-Rosemont Hôpital Service d'Hematologie et d'Oncologie Medicale

location_facility: Fundació Hospital de la Santa Creu i Sant Pau

location_facility: Sahlgrenska Universitetssjukhuset, Östra sjukhuset

location_facility: Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie

location_facility: Hospital Universitari i Politecnic La Fe de Valencia

location_facility: West Virginia University Mary Babb Randolph Cancer Center

location_facility: Onkologická klinika Všeobecná fakultní nemocnice v Praze a 1

location_facility: Desert Hematology Oncology Medical Group, Inc.

location_facility: Penn State Milton S. Hershey Medical Center

location_facility: Hospital Universitari Germans Trias i Pujol

location_facility: Nottingham University Hospitals NHS Trust

location_facility: Algemeen Ziekenhuis Sint-Jan Brugge-Oostende

intervention_type: Other


title: A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

acronym: HERCULES

summary: The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

ReferenceCitation: Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021 Apr 27;5(8):2137-2141. doi: 10.1182/bloodadvances.2020001834.

name: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;

name: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy;

family: Peyvandi

full_name: Flora Peyvandi

given: Flora

name: Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;

family: Cataland

full_name: Spero Cataland

given: Spero

name: Department of Haematology, University College London Hospital National Health Service Trust, London, United Kingdom;

family: Scully

full_name: Marie Scully

given: Marie

name: Department of Hematology, Reference Center for Thrombotic Microangiopathies, Saint-Antoine University Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France;

family: Coppo

full_name: Paul Coppo

given: Paul

name: Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria;

family: Knoebl

full_name: Paul Knoebl

name: Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland;

family: Kremer Hovinga

full_name: Johanna A. Kremer Hovinga

given: Johanna A.

name: Department of Medicine, Duke University School of Medicine, Durham, NC;

family: Metjian

full_name: Ara Metjian

given: Ara

name: Hematology Department, Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia and Hospital Doctor Peset, Valencia, Spain;

family: de la Rubia

full_name: Javier de la Rubia

given: Javier

name: Departments of Laboratory Medicine and Medicine, St. Michael’s Hospital, Toronto, Canada;

name: Departments of Laboratory Medicine and Pathobiology and Medicine, University of Toronto, Toronto, Canada;

family: Pavenski

full_name: Katerina Pavenski

given: Katerina

name: Clinical Development, Ablynx, a Sanofi company, Ghent, Belgium; and

family: Minkue Mi Edou

full_name: Jessica Minkue Mi Edou

given: Jessica

family: De Winter

full_name: Hilde De Winter

given: Hilde

name: Medical Affairs, Sanofi, Diegem, Belgium

family: Callewaert

full_name: Filip Callewaert

given: Filip

journal_name: Blood Advances

oa_colors: green gold

oa_host_type: publisher;repository

evidence: open (via free article)

host_type: publisher

license_normalized: no license

version: publishedVersion

evidence: oa repository (via pmcid lookup)

host_type: repository

repository_normalized: PubMed Central

publisher: American Society of Hematology

publisher_dissemination: American Society of Hematology

publisher_group: American Society of Hematology

publisher_normalized: American Society of Hematology

ReferenceCitation: Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020 Feb;18(2):479-484. doi: 10.1111/jth.14679. Epub 2019 Dec 9.

name: Division of Hematology and Hemostasis Department of Medicine 1 Medical University of Vienna Wien Austria

name: Division of Hematology Department of Internal Medicine The Ohio State University Columbus OH USA

name: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

name: Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

name: Department of Hematology Reference Center for Thrombotic Microangiopathies (CNR‐MAT) Saint‐Antoine University Hospital AP‐HP Paris France

name: Cardiometabolic Programme‐NIHR UCLH/UCL BRC Department of Haematology University College London Hospital London UK

name: Department of Hematology and Central Hematology Laboratory, Inselspital Bern University Hospital University of Bern Bern Switzerland

name: Department of Medicine Duke University School of Medicine Durham NC USA

name: Hematology Department, Internal Medicine School of Medicine and Dentistry Catholic University of Valencia Valencia Spain

name: Departments of Medicine and Laboratory Medicine St. Michael's Hospital University of Toronto Toronto ON Canada

name: Formerly Clinical Development Ablynx, a Sanofi Company Ghent Belgium

repository_institution: Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca

repository_institution: University Library Bern - BORIS - Bern Open Repository and Information System

title: Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

ReferenceCitation: Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

name: From the Department of Haematology, University College London Hospitals, Cardiometabolic Program, National Institute for Health Research UCLH–UCL Biomedical Research Center, London (M.S.); the Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus (S.R.C.); Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, and the Department of Pathophysiology and...

repository_institution: University of Zurich - Zurich Open Repository and Archive

location_country:
Italy
Austria
United States
Switzerland
Netherlands
Germany
France
Czechia
Israel
Hungary
Australia
Belgium
Spain
Turkey
Canada
United Kingdom

location_facility:
Investigator Site 5
Investigator site 1
Investigator SIte
Investigator site 5
Investigator Site 4
Investigator Site 2
Invesigator Site
Investigator site 3
Investigator Site
Investigator site
Investigator Site 3
Investigator Site 1
Investigator site 2


title: Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments

summary: The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.

ReferenceCitation: Tabernero J, Alsina M, Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Ando T, Yalçın Ş, Van Cutsem E, Sabater J, Skanji D, Leger C, Amellal N, Ilson DH. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. Gastric Cancer. 2020 Jul;23(4):689-698. doi: 10.1007/s10120-020-01053-9. Epub 2020 Mar 4.

family: Tabernero

full_name: Josep Tabernero

given: Josep

family: Alsina

full_name: Maria Alsina

given: Maria

family: Shitara

full_name: Kohei Shitara

given: Kohei

family: Doi

full_name: Toshihiko Doi

given: Toshihiko

family: Dvorkin

full_name: Mikhail Dvorkin

given: Mikhail

family: Mansoor

full_name: Wasat Mansoor

given: Wasat

family: Arkenau

full_name: Hendrik-Tobias Arkenau

given: Hendrik-Tobias

family: Prokharau

full_name: Aliaksandr Prokharau

given: Aliaksandr

family: Ghidini

full_name: Michele Ghidini

given: Michele

family: Faustino

full_name: Catia Faustino

given: Catia

family: Gorbunova

full_name: Vera Gorbunova

given: Vera

family: Zhavrid

full_name: Edvard Zhavrid

given: Edvard

family: Nishikawa

full_name: Kazuhiro Nishikawa

given: Kazuhiro

family: Ando

full_name: Takayuki Ando

given: Takayuki

family: Yalçın

full_name: Şuayib Yalçın

given: Şuayib

family: Van Cutsem

full_name: Eric Van Cutsem

given: Eric

family: Sabater

full_name: Javier Sabater

family: Skanji

full_name: Donia Skanji

given: Donia

family: Leger

full_name: Catherine Leger

given: Catherine

family: Amellal

full_name: Nadia Amellal

given: Nadia

family: Ilson

full_name: David H. Ilson

given: David H.

journal_name: Gastric Cancer

oa_colors: green hybrid

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: University College London - UCL Discovery

repositories:
LIRIAS (KU Leuven)
PubMed Central
UCL Discovery

ReferenceCitation: Ilson DH, Tabernero J, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience P, Beretta GD, Mansoor W, Zhavrid E, Alsina M, George B, Catenacci D, McGuigan S, Makris L, Doi T, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. JAMA Oncol. 2020 Jan 1;6(1):e193531. doi: 10.1001/jamaoncol.2019.3531. Epub 2020 Jan 9.

name: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

name: Department of Medical Oncology, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain

name: Department of Oncology, Minsk City Clinical Oncology Dispensary, Minsk, Belarus

name: Drug Development Unit, Sarah Cannon Research Institute, Cancer Institute, University College London, London, United Kingdom

name: Department of Oncology, Azienda Ospedaliera di Cremona, Cremona, Italy

name: Department of Surgery, Osaka General Medical Center, Osaka, Japan

name: Digestive Oncology, University Hospitals Gasthuisberg Leuven, KU Leuven, Leuven, Belgium

name: Department of Hematology, Oncology, and Tumor Immunology, Charité–Universitätsmedizin Berlin, Berlin, Germany

name: Department of Oncology, Humanitas Gavazzeni, Bergamo, Italy

name: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom

name: Department of Chemotherapy, Alexandrov National Cancer Centre of Belarus, Minsk, Belarus

name: Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee

name: Department of Medicine, University of Chicago, Chicago, Illinois

name: Medical Affairs Division, Taiho Oncology Inc, Princeton, New Jersey

name: Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan

ReferenceCitation: Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668.

ReferenceCitation: Bando H, Doi T, Muro K, Yasui H, Nishina T, Yamaguchi K, Takahashi S, Nomura S, Kuno H, Shitara K, Sato A, Ohtsu A. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer. 2016 Jul;62:46-53. doi: 10.1016/j.ejca.2016.04.009. Epub 2016 May 19.

location_country:
Italy
United States
Spain
Germany
France
Czechia
Japan
Israel
Poland
Romania
Ireland
Belgium
Russian Federation
Belarus
Turkey
Canada
United Kingdom
Portugal

location_facility: Belfast Health and Social Care Trust - Belfast City Hospital

location_facility: Azienda Ospedaliero Universitaria Pisana (AOUP)

location_facility: Unidade Local de Saúde de Matosinhos E.P.E.- H. Pedro Hispano

location_facility: Diskapi Yildirim Beyazit Training and Research Hospital

location_facility: Szpital MSWiA i Warminsko - Mazurskim Centrum Onkologii w Olsztynie

location_facility: IRCCS - Istituto Scientifico Romagnolo Per lo Studio e la Cura Dei Tumori (I.R.S.T.)

location_facility: A.O. della Valtellina e della Valchiavenna Ospedale di Sondrio

location_facility: Budget Institution of Healthcare Omsk Region -Clinical Oncology Dispensary

location_facility: Fondazione Poliambulanza Istituto Ospedaliero

location_facility: North-Western State Medical University n.a. I.I. Mechnikov

location_facility: Baskent University Adana Practice and Research Centre Kisla

location_facility: Spitalul Judetean de Urgenta "Sfantul Ioan cel Nou" Suceava

location_facility: Dartmouth-Hitchcock Medical Center (DHMC)

location_facility: University of Southern California - Keck School of Medicine

location_facility: Hospital Universitario Central de Asturias

location_facility: Guy's and St Thomas' NHS Foundation Trust

location_facility: Gomel Regional Clinical Oncology Dispensary

location_facility: A.O.U. Seconda Universita'degli Studi di Napoli

location_facility: Dokuz Eylul University Oncology Institute

location_facility: N.N.Petrov Research Institute of Oncology

location_facility: Trakya University Medical Faculty Hospital

location_facility: Bezmialem Vakif Üniversitesi Tip Fakültesi Hastanesi

location_facility: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology

location_facility: AP-HP - HU La Pitié-Salpêtrière - Charles-Foix

location_facility: IRCCS Centro di Riferimento Oncologico - Aviano

location_facility: Staedtisches Krankenhaus Muenchen Neuperlach

location_facility: Azienda Ospedaliero - Universitaria Careggi

location_facility: Ankara University Medical Faculty Cebeci Hospital

location_facility: The Adelaide and Meath Hospital, Dublin, Incorporating The National Children's Hospital

location_facility: Republican center for oncology and medical radiology n.a. Alexandrov

location_facility: University of Pittsburgh Medical Cancer Center

location_facility: Alta Bates Summit Comprehensive Cancer Center

location_facility: Centro Hospitalar de Tras-os-Montes e Alto Douro, EPE

location_facility: N.N. Blokhin Russian Cancer Research Center

location_facility: Górnoslaskie Centrum Medyczne im. prof. Leszka Gieca

location_facility: Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research

location_facility: Marmara University Pendik Training and Research Hospital

location_facility: Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E.


title: A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

summary: Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.

ReferenceCitation: Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.

ReferenceCitation: O'Brien EC, Raman SR, Ellis A, Hammill BG, Berdan LG, Rorick T, Janmohamed S, Lampron Z, Hernandez AF, Curtis LH. The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study. Trials. 2021 Jul 19;22(1):465. doi: 10.1186/s13063-021-05397-0.

family: O’Brien

full_name: Emily C. O’Brien

given: Emily C.

family: Raman

full_name: Sudha R. Raman

given: Sudha R.

family: Ellis

full_name: Alicia Ellis

given: Alicia

family: Hammill

full_name: Bradley G. Hammill

given: Bradley G.

family: Berdan

full_name: Lisa G. Berdan

given: Lisa G.

family: Rorick

full_name: Tyrus Rorick

given: Tyrus

family: Janmohamed

full_name: Salim Janmohamed

given: Salim

family: Lampron

full_name: Zachary Lampron

given: Zachary

family: Hernandez

full_name: Adrian F. Hernandez

given: Adrian F.

family: Curtis

full_name: Lesley H. Curtis

given: Lesley H.

currency_apc_doaj: GBP

journal_name: Trials

evidence: oa journal (via doaj)

license: cc-by

license_normalized: cc-by

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

ReferenceCitation: Green JB, Hernandez AF, D'Agostino RB, Granger CB, Janmohamed S, Jones NP, Leiter LA, Noronha D, Russell R, Sigmon K, Del Prato S, McMurray JJV. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. Am Heart J. 2018 Sep;203:30-38. doi: 10.1016/j.ahj.2018.03.030. Epub 2018 Jun 12.

family: Green

full_name: Jennifer B. Green

given: Jennifer B.

family: D’Agostino

full_name: Ralph B. D’Agostino

given: Ralph B.

family: Granger

full_name: Chris B. Granger

given: Chris B.

family: Jones

full_name: Nigel P. Jones

given: Nigel P.

family: Leiter

full_name: Lawrence A. Leiter

given: Lawrence A.

title: Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics

ReferenceCitation: Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155.

location_country:
Peru
Greece
Belgium
Russian Federation
Denmark
Taiwan
Ukraine
France
Poland
Thailand
Norway
Argentina
Canada
Korea, Republic of
South Africa
Sweden
Hong Kong
Netherlands
Philippines
Bulgaria
Hungary
United States
Germany
United Kingdom
Italy
Mexico
Czechia
Spain


title: A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

summary: This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.

lead_sponsor: Pharmacyclics LLC.

location_country:
Italy
United States
France
Belgium
Spain
Germany
United Kingdom
Korea, Republic of

location_facility: IRCCS Ospedale Casa Sollievo della Sofferenza

location_facility: Gemeinschaftspraxis Haematologie und Onkologie

location_facility: Klinikum der Johann Wolfgang Goethe-Universitaet

location_facility: Oncology Specialties, PC; Clearview Cancer Institute

location_facility: Nebraska Medicine - Peggy D. Cowdery Patient Care Center

location_facility: Joliet Oncology-Hematology Associates, LTD

location_facility: Chonnam National University Hwasun Hospital

location_facility: Azienda Ospedaliero Universitaria Pisana

location_facility: Berkshire Hematology Oncology Services at Berkshire Medical Center Cancer and Infusion Center

location_facility: Hospital Clinico Universitario Virgen de la Victoria

location_facility: Hospital Clinic i Provincial de Barcelona

location_facility: Azienda Ospedaliero Universitaria San Martino

location_facility: Penn State University Milton S. Hershey Medical Center

location_facility: The Catholic University of Korea, Seoul St. Mary's Hospital

location_facility: Seoul National University Bundang Hospital

location_facility: ICO l´Hospitalet - Hospital Duran i Reynals

location_facility: Azienda Ospedaliera Ospedale Niguarda Ca' Granda

location_facility: Investigative Clinical Research of Indiana

location_facility: Eastern Connecticut Hematology/Oncology Assoc.

location_facility: Azienda Ospedaliero Universitaria Ospedali Riuniti

location_facility: Groupe Hospitalier Saint André - Hôpital Saint André

location_facility: MultiCare Health System Institute for Research and Innovation

location_facility: Ingalls Memorial Hospital Cancer Research Center

location_facility: Istituto Nazionale Tumori Fondazione G. Pascale


ReferenceCitation: Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387.

ReferenceCitation: Trojan J, Mollon P, Daniele B, Marteau F, Martín L, Li Y, Xu Q, Piscaglia F, Zaucha R, Sarker D, Lim HY, Venerito M. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. Adv Ther. 2021 May;38(5):2472-2490. doi: 10.1007/s12325-021-01700-2. Epub 2021 Apr 6.

family: Trojan

full_name: Jörg Trojan

given: Jörg

family: Mollon

full_name: Patrick Mollon

given: Patrick

family: Daniele

full_name: Bruno Daniele

given: Bruno

family: Marteau

full_name: Florence Marteau

given: Florence

family: Martín

full_name: Lidia Martín

given: Lidia

family: Li

full_name: Yuxin Li

given: Yuxin

family: Xu

full_name: Qing Xu

given: Qing

family: Piscaglia

full_name: Fabio Piscaglia

given: Fabio

family: Zaucha

full_name: Renata Zaucha

given: Renata

family: Sarker

full_name: Debashis Sarker

given: Debashis

family: Lim

full_name: Ho Yeong Lim

given: Ho Yeong

family: Venerito

full_name: Marino Venerito

given: Marino

journal_name: Advances in Therapy

evidence: open (via crossref license)

license: cc-by-nc

license_normalized: cc-by-nc

ReferenceCitation: Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 Apr;124(8):1388-1397. doi: 10.1038/s41416-021-01260-w. Epub 2021 Feb 3.

family: Zhu

full_name: Andrew X. Zhu

given: Andrew X.

family: Finn

full_name: Richard S. Finn

given: Richard S.

family: Kang

full_name: Yoon-Koo Kang

given: Yoon-Koo

family: Yen

full_name: Chia-Jui Yen

given: Chia-Jui

family: Galle

full_name: Peter R. Galle

given: Peter R.

family: Llovet

full_name: Josep M. Llovet

given: Josep M.

family: Assenat

full_name: Eric Assenat

given: Eric

ReferenceCitation: Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021 Mar;41(3):598-607. doi: 10.1111/liv.14731. Epub 2020 Dec 5.

name: Barcelona Clinic Liver Cancer Group, Liver Unit Hospital Clínic of Barcelona. IDIBAPS. CIBERehd. University of Barcelona Barcelona Spain

name: Department of Internal Medicine Mainz University Medical Center Mainz Germany

name: Departments of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan

name: Division of Hematology/Oncology University of California Los Angeles CA USA

name: Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York NY USA

name: Translational Research in Hepatic Oncology, Liver Unit IDIBAPS, Hospital Clinic Barcelona, University of Barcelona Barcelona Spain

name: Institució Catalana d’Estudis Avançats (ICREA) Barcelona Spain

name: Eli Lilly and Company Indianapolis IN USA

name: Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA

name: Jiahui International Cancer Center Jiahui Health Shanghai China

repository_institution: Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona

ReferenceCitation: Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Wang C, Hsu Y, Abada PB, Kudo M. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open. 2020 Aug;5(4). pii: e000797. doi: 10.1136/esmoopen-2020-000797.

ReferenceCitation: Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol. 2020 Jun;55(6):627-639. doi: 10.1007/s00535-020-01668-w. Epub 2020 Feb 27.

ReferenceCitation: Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

ipd_sharing_description:
Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.

This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

location_country:
Italy
Austria
Brazil
Hong Kong
Spain
Switzerland
Germany
France
Czechia
Japan
Israel
Korea, Republic of
Poland
Australia
Belgium
China
United States
United Kingdom
Canada
Taiwan

location_facility: Cenantron - Centro Avançado de Tratamento Oncológico

location_facility: University of Oklahoma Health Sciences Center

location_facility: Hospital Universitari de Girona Dr. Josep Trueta

location_facility: For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.

location_facility: "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."

location_facility: Pacific Hematology and Oncology Associates

title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

summary: The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment [ME2] Cohort). Participants may also receive ramucirumab if eligible to be enrolled in Open-Label Expansion (OLE) Cohort.


type: Other Identifier

title: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe Disease

acronym: COMET

summary:
Primary Objective:

To determine the effect of avalglucosidase alfa treatment on respiratory muscle strength measured by percent (%) predicted forced vital capacity (FVC) in the upright position, as compared to alglucosidase alfa.

Secondary Objective:

To determine the safety and effect of avalglucosidase alfa treatment on functional endurance (6-minute walk test, inspiratory muscle strength (maximum inspiratory pressure), expiratory muscle strength (maximum expiratory pressure), lower extremity muscle strength (hand-held dynamometry), motor function (Quick Motor Function Test), and health-related quality of life (Short Form-12).

ReferenceCitation: Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6.

family: Diaz-Manera

full_name: Jordi Diaz-Manera

given: Jordi

family: Kishnani

full_name: Priya S Kishnani

given: Priya S

family: Kushlaf

full_name: Hani Kushlaf

given: Hani

family: Ladha

full_name: Shafeeq Ladha

given: Shafeeq

family: Mozaffar

full_name: Tahseen Mozaffar

given: Tahseen

family: Straub

full_name: Volker Straub

given: Volker

family: Toscano

full_name: Antonio Toscano

given: Antonio

family: van der Ploeg

full_name: Ans T van der Ploeg

given: Ans T

family: Berger

full_name: Kenneth I Berger

given: Kenneth I

family: Clemens

full_name: Paula R Clemens

given: Paula R

family: Chien

full_name: Yin-Hsiu Chien

given: Yin-Hsiu

family: Day

full_name: John W Day

given: John W

family: Illarioshkin

full_name: Sergey Illarioshkin

given: Sergey

family: Roberts

full_name: Mark Roberts

given: Mark

family: Attarian

full_name: Shahram Attarian

given: Shahram

family: Borges

full_name: Joao Lindolfo Borges

given: Joao Lindolfo

family: Bouhour

full_name: Francoise Bouhour

given: Francoise

family: Choi

full_name: Young Chul Choi

given: Young Chul

family: Erdem-Ozdamar

full_name: Sevim Erdem-Ozdamar

given: Sevim

family: Goker-Alpan

full_name: Ozlem Goker-Alpan

given: Ozlem

family: Kostera-Pruszczyk

full_name: Anna Kostera-Pruszczyk

given: Anna

family: Haack

full_name: Kristina An Haack

given: Kristina An

family: Hug

ipd_sharing_description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/.

location_country:
Australia
Belgium
Russian Federation
Denmark
Taiwan
France
Japan
Poland
Argentina
Canada
Korea, Republic of
Switzerland
Netherlands
Hungary
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Czechia
Spain
Turkey

location_facility:
Investigational Site Number 8400012
Investigational Site Number 3800001
Investigational Site Number 7920002
Investigational Site Number 8260002
Investigational Site Number 3800003
Investigational Site Number 4100002
Investigational Site Number 8400008
Investigational Site Number 8400009
Investigational Site Number 8400001
Investigational Site Number 4100001
Investigational Site Number 2760003
Investigational Site Number 7240003
Investigational Site Number 8400024
Investigational Site Number 8260003
Investigational Site Number 7240002
Investigational Site Number 1240002
Investigational Site Number 5280001
Investigational Site Number 0400001
Investigational Site Number 2030001
Investigational Site Number 6200001
Investigational Site Number 3800006
Investigational Site Number 2500008
Investigational Site Number 7920001
Investigational Site Number 8260004
Investigational Site Number 3800002
Investigational Site Number 0560003
Investigational Site Number 8400023
Investigational Site Number 0760001
Investigational Site Number 2760001
Investigational Site Number 2080003
Investigational Site Number 6430001
Investigational Site Number 8400020
Investigational Site Number 4840001
Investigational Site Number 2500001
Investigational Site Number 7560002
Investigational Site Number 2500011
Investigational Site Number 8400019
Investigational Site Number 8400016
Investigational Site Number 0360001
Investigational Site Number 8400026
Investigational Site Number 2500004
Investigational Site Number 2500006
Investigational Site Number 2760002
Investigational Site Number 3800007
Investigational Site Number 8260005
Investigational Site Number 0560001
Investigational Site Number 2760006
Investigational Site Number 8400006
Investigational Site Number 3480001
Investigational Site Number 8400010
Investigational Site Number 8400025
Investigational Site Number 3920002
Investigational Site Number 0760004
Investigational Site Number 0320001
Investigational Site Number 2500010
Investigational Site Number 8400002
Investigational Site Number 8400017
Investigational Site Number 1240003
Investigational Site Number 8260001
Investigational Site Number 8400015
Investigational Site Number 2500007
Investigational Site Number 8400011
Investigational Site Number 1580001
Investigational Site Number 8400005
Investigational Site Number 8400014
Investigational Site Number 6160001
Investigational Site Number 8400018
Investigational Site Number 2500005
Investigational Site Number 8400007


title: A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

summary:
Primary Objective:

To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma.

Secondary Objectives:

To evaluate the safety and tolerability of dupilumab.
To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life.
To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.

ReferenceType: result

ReferenceCitation: Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

name: From the Washington University School of Medicine, St. Louis (M.C.); David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J. Corren), and Peninsula Research Associates, Rolling Hills Estates (L.S.) — both in California; Oxford Respiratory National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, United Kingdom (I.D.P.); Fundación CIDEA (Centro de Investigación de Enfermedades Alérgicas y Respiratorias), Buenos Aires (J.M.); the...

family: Castro

full_name: Mario Castro

given: Mario

family: Corren

full_name: Jonathan Corren

given: Jonathan

family: Pavord

full_name: Ian D. Pavord

given: Ian D.

family: Maspero

full_name: Jorge Maspero

given: Jorge

family: Wenzel

full_name: Sally Wenzel

given: Sally

family: Rabe

full_name: Klaus F. Rabe

given: Klaus F.

family: Busse

full_name: William W. Busse

given: William W.

family: Ford

full_name: Linda Ford

given: Linda

family: Sher

full_name: Lawrence Sher

given: Lawrence

family: FitzGerald

full_name: J. Mark FitzGerald

given: J. Mark

family: Katelaris

full_name: Constance Katelaris

given: Constance

family: Tohda

full_name: Yuji Tohda

given: Yuji

family: Zhang

full_name: Bingzhi Zhang

given: Bingzhi

family: Staudinger

full_name: Heribert Staudinger

given: Heribert

family: Pirozzi

full_name: Gianluca Pirozzi

given: Gianluca

family: Amin

full_name: Nikhil Amin

given: Nikhil

family: Ruddy

full_name: Marcella Ruddy

given: Marcella

family: Akinlade

full_name: Bolanle Akinlade

given: Bolanle

family: Khan

full_name: Asif Khan

given: Asif

family: Chao

full_name: Jingdong Chao

given: Jingdong

family: Martincova

full_name: Renata Martincova

given: Renata

family: Graham

full_name: Neil M.H. Graham

given: Neil M.H.

family: Hamilton

full_name: Jennifer D. Hamilton

given: Jennifer D.

repository_institution: University of Oxford - Oxford University Research Archive (ORA)

ReferenceCitation: Busse WW, Paggiaro P, Muñoz X, Casale TB, Castro M, Canonica GW, Douglass JA, Tohda Y, Daizadeh N, Ortiz B, Pandit-Abid N. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. Eur Respir J. 2021 Oct 7;58(4). pii: 2004605. doi: 10.1183/13993003.04605-2020. Print 2021 Oct.

ReferenceCitation: Corren J, Katelaris CH, Castro M, Maspero JF, Ford LB, Halpin DMG, Rice MS, Radwan A, Deniz Y, Rowe PJ, Teper A, Djandji M. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. Eur Respir J. 2021 Oct 28;58(4). pii: 2004498. doi: 10.1183/13993003.04498-2020. Print 2021 Oct.

title: Effect of exacerbation history on clinical response to dupilumab in moderate-severe uncontrolled asthma

ReferenceCitation: Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021 Oct;9(10):1165-1173. doi: 10.1016/S2213-2600(21)00124-7. Epub 2021 Jun 25.

ReferenceCitation: Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pirozzi G, Mannent L, Graham NMH. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26.

name: Regeneron Pharmaceuticals, Inc Tarrytown NY USA

ReferenceCitation: Maspero JF, FitzGerald JM, Pavord ID, Rice MS, Maroni J, Rowe PJ, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A, Hardin M. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy. 2021 Aug;76(8):2621-2624. doi: 10.1111/all.14872. Epub 2021 May 10.

name: University of British Columbia Vancouver BC Canada

name: Respiratory Medicine Unit and Oxford Respiratory National Institute for Health Research Biomedical Research CentreUniversity of Oxford Oxford UK

name: Regeneron Pharmaceuticals Inc. Tarrytown NY USA

title: Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST

ReferenceCitation: Bansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, de Bruin-Weller M, Corren J, Sher L, Guttman-Yassky E, Chen Z, Daizadeh N, Kamal MA, Shumel B, Mina-Osorio P, Mannent L, Patel N, Graham NMH, Khokhar FA, Ardeleanu M. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1.

journal_name: American Journal of Clinical Dermatology

ReferenceCitation: Bourdin A, Papi AA, Corren J, Virchow JC, Rice MS, Deniz Y, Djandji M, Rowe P, Pavord ID. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021 Jan;76(1):269-280. doi: 10.1111/all.14611. Epub 2020 Oct 21.

name: Department of Respiratory Diseases INSERM U1046 University of Montpellier Montpellier France

name: Università degli Studi di Ferrara Ferrara Italy

name: David Geffen School of Medicine at UCLA Los Angeles CA USA

name: Universitätsmedizin Rostock Rostock Germany

name: Regeneron Pharmaceuticals, Inc. Tarrytown NY USA

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Diderot

title: Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline

ReferenceCitation: Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Arima K, Miyata M, Takahashi Y, Rice MS, Deniz Y, Rowe P, Patel N, Graham NMH, Teper A. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergol Int. 2020 Oct;69(4):578-587. doi: 10.1016/j.alit.2020.04.002. Epub 2020 May 20.

ReferenceCitation: Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526. doi: 10.1016/j.jaip.2019.08.050. Epub 2019 Sep 12.

journal_name: The Journal of Allergy and Clinical Immunology: In Practice

ReferenceCitation: Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2020 Feb;8(2):527-539.e9. doi: 10.1016/j.jaip.2019.07.016. Epub 2019 Jul 24.

ReferenceCitation: Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbé A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2. doi: 10.1016/j.anai.2018.08.005. Epub 2018 Aug 21.

ReferenceCitation: Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.

repository_institution: University of Ferrara - Institutional Research Information System University of Ferrara

ReferenceCitation: Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1. doi: 10.1016/j.jaci.2017.11.051. Epub 2018 Jan 31.

location_country:
Australia
Russian Federation
Taiwan
Ukraine
France
Japan
Poland
Argentina
Canada
Korea, Republic of
Colombia
South Africa
Chile
Hungary
United States
Germany
United Kingdom
Italy
Brazil
Mexico
Spain
Turkey

location_facility:
Investigational Site Number 124015
Investigational Site Number 124007
Investigational Site Number 840061
Investigational Site Number 840053
Investigational Site Number 616009
Investigational Site Number 158005
Investigational Site Number 616002
Investigational Site Number 710002
Investigational Site Number 804003
Investigational Site Number 392137
Investigational Site Number 840056
Investigational Site Number 076003
Investigational Site Number 792002
Investigational Site Number 392187
Investigational Site Number 710004
Investigational Site Number 124012
Investigational Site Number 840057
Investigational Site Number 124003
Investigational Site Number 392147
Investigational Site Number 840007
Investigational Site Number 392155
Investigational Site Number 124013
Investigational Site Number 840112
Investigational Site Number 840009
Investigational Site Number 392150
Investigational Site Number 643007
Investigational Site Number 276010
Investigational Site Number 250013
Investigational Site Number 643002
Investigational Site Number 840097
Investigational Site Number 840001
Investigational Site Number 392169
Investigational Site Number 392138
Investigational Site Number 410003
Investigational Site Number 076002
Investigational Site Number 840071
Investigational Site Number 152007
Investigational Site Number 643009
Investigational Site Number 392134
Investigational Site Number 840122
Investigational Site Number 840125
Investigational Site Number 840041
Investigational Site Number 840037
Investigational Site Number 840050
Investigational Site Number 840099
Investigational Site Number 036006
Investigational Site Number 840015
Investigational Site Number 152009
Investigational Site Number 392112
Investigational Site Number 032007
Investigational Site Number 840070
Investigational Site Number 380010
Investigational Site Number 840051
Investigational Site Number 840105
Investigational Site Number 840130
Investigational Site Number 076012
Investigational Site Number 792004
Investigational Site Number 380002
Investigational Site Number 392139
Investigational Site Number 392165
Investigational Site Number 152010
Investigational Site Number 392154
Investigational Site Number 392177
Investigational Site Number 826006
Investigational Site Number 392184
Investigational Site Number 276001
Investigational Site Number 840027
Investigational Site Number 392151
Investigational Site Number 840073
Investigational Site Number 826001
Investigational Site Number 484012
Investigational Site Number 392107
Investigational Site Number 484007
Investigational Site Number 152015
Investigational Site Number 840004
Investigational Site Number 392162
Investigational Site Number 840078
Investigational Site Number 124019
Investigational Site Number 616005
Investigational Site Number 840087
Investigational Site Number 840003
Investigational Site Number 840107
Investigational Site Number 840081
Investigational Site Number 616003
Investigational Site Number 804007
Investigational Site Number 392121
Investigational Site Number 392173
Investigational Site Number 840119
Investigational Site Number 840029
Investigational Site Number 392118
Investigational Site Number 392123
Investigational Site Number 840104
Investigational Site Number 643003
Investigational Site Number 380014
Investigational Site Number 392101
Investigational Site Number 616007
Investigational Site Number 792006
Investigational Site Number 840016
Investigational Site Number 410006
Investigational Site Number 840089
Investigational Site Number 840109
Investigational Site Number 392119
Investigational Site Number 643010
Investigational Site Number 724001
Investigational Site Number 804002
Investigational Site Number 392102
Investigational Site Number 170006
Investigational Site Number 792011
Investigational Site Number 392174
Investigational Site Number 380005
Investigational Site Number 392108
Investigational Site Number 392152
Investigational Site Number 392170
Investigational Site Number 840074
Investigational Site Number 250010
Investigational Site Number 152011
Investigational Site Number 392122
Investigational Site Number 410008
Investigational Site Number 076013
Investigational Site Number 410012
Investigational Site Number 392133
Investigational Site Number 158004
Investigational Site Number 276003
Investigational Site Number 840121
Investigational Site Number 840093
Investigational Site Number 724002
Investigational Site Number 032012
Investigational Site Number 840045
Investigational Site Number 840080
Investigational Site Number 840042
Investigational Site Number 124014
Investigational Site Number 250002
Investigational Site Number 804021
Investigational Site Number 392153
Investigational Site Number 484010
Investigational Site Number 840083
Investigational Site Number 826005
Investigational Site Number 032009
Investigational Site Number 804004
Investigational Site Number 036004
Investigational Site Number 724005
Investigational Site Number 392149
Investigational Site Number 392166
Investigational Site Number 158008
Investigational Site Number 840035
Investigational Site Number 392167
Investigational Site Number 380001
Investigational Site Number 840091
Investigational Site Number 392178
Investigational Site Number 152016
Investigational Site Number 643001
Investigational Site Number 392115
Investigational Site Number 710009
Investigational Site Number 840092
Investigational Site Number 170003
Investigational Site Number 392109
Investigational Site Number 392132
Investigational Site Number 804017
Investigational Site Number 250011
Investigational Site Number 840039
Investigational Site Number 484008
Investigational Site Number 840002
Investigational Site Number 484006
Investigational Site Number 380006
Investigational Site Number 804006
Investigational Site Number 124006
Investigational Site Number 158009
Investigational Site Number 076009
Investigational Site Number 804014
Investigational Site Number 392183
Investigational Site Number 392158
Investigational Site Number 392136
Investigational Site Number 392186
Investigational Site Number 158006
Investigational Site Number 392120
Investigational Site Number 840094
Investigational Site Number 152005
Investigational Site Number 643008
Investigational Site Number 840129
Investigational Site Number 410002
Investigational Site Number 840066
Investigational Site Number 152003
Investigational Site Number 152004
Investigational Site Number 036005
Investigational Site Number 276005
Investigational Site Number 804016
Investigational Site Number 643005
Investigational Site Number 840065
Investigational Site Number 840062
Investigational Site Number 840044
Investigational Site Number 392172
Investigational Site Number 840077
Investigational Site Number 840106
Investigational Site Number 410014
Investigational Site Number 410004
Investigational Site Number 032006
Investigational Site Number 616008
Investigational Site Number 792008
Investigational Site Number 276006
Investigational Site Number 710003
Investigational Site Number 840117
Investigational Site Number 152008
Investigational Site Number 392142
Investigational Site Number 840047
Investigational Site Number 032002
Investigational Site Number 410007
Investigational Site Number 840082
Investigational Site Number 036002
Investigational Site Number 840028
Investigational Site Number 124018
Investigational Site Number 410009
Investigational Site Number 392113
Investigational Site Number 643013
Investigational Site Number 032004
Investigational Site Number 840014
Investigational Site Number 840111
Investigational Site Number 124009
Investigational Site Number 250001
Investigational Site Number 484003
Investigational Site Number 840020
Investigational Site Number 276009
Investigational Site Number 826003
Investigational Site Number 840059
Investigational Site Number 392157
Investigational Site Number 032011
Investigational Site Number 250003
Investigational Site Number 124001
Investigational Site Number 840052
Investigational Site Number 804011
Investigational Site Number 804008
Investigational Site Number 840013
Investigational Site Number 410010
Investigational Site Number 410005
Investigational Site Number 380011
Investigational Site Number 792001
Investigational Site Number 804022
Investigational Site Number 840046
Investigational Site Number 158007
Investigational Site Number 392131
Investigational Site Number 392144
Investigational Site Number 380004
Investigational Site Number 152014
Investigational Site Number 392164
Investigational Site Number 840064
Investigational Site Number 392114
Investigational Site Number 158002
Investigational Site Number 840096
Investigational Site Number 840115
Investigational Site Number 840054
Investigational Site Number 724006
Investigational Site Number 152012
Investigational Site Number 032005
Investigational Site Number 076001
Investigational Site Number 392168
Investigational Site Number 392110
Investigational Site Number 840022
Investigational Site Number 840055
Investigational Site Number 250014
Investigational Site Number 804013
Investigational Site Number 840132
Investigational Site Number 840026
Investigational Site Number 036001
Investigational Site Number 792009
Investigational Site Number 250012
Investigational Site Number 484011
Investigational Site Number 840017
Investigational Site Number 840098
Investigational Site Number 616001
Investigational Site Number 840101
Investigational Site Number 380009
Investigational Site Number 724004
Investigational Site Number 484014
Investigational Site Number 792010
Investigational Site Number 392135
Investigational Site Number 804012
Investigational Site Number 170001
Investigational Site Number 840012
Investigational Site Number 124010
Investigational Site Number 840102
Investigational Site Number 392127
Investigational Site Number 616004
Investigational Site Number 152017
Investigational Site Number 826007
Investigational Site Number 250005
Investigational Site Number 392146
Investigational Site Number 792005
Investigational Site Number 840100
Investigational Site Number 392125
Investigational Site Number 710006
Investigational Site Number 710011
Investigational Site Number 840031
Investigational Site Number 840085
Investigational Site Number 840038
Investigational Site Number 724010
Investigational Site Number 410011
Investigational Site Number 804005
Investigational Site Number 840011
Investigational Site Number 840008
Investigational Site Number 840076
Investigational Site Number 840084
Investigational Site Number 380003
Investigational Site Number 410001
Investigational Site Number 840068
Investigational Site Number 643006
Investigational Site Number 392176
Investigational Site Number 792003
Investigational Site Number 840043
Investigational Site Number 724007
Investigational Site Number 792007
Investigational Site Number 840116
Investigational Site Number 840126
Investigational Site Number 152002
Investigational Site Number 840049
Investigational Site Number 124008
Investigational Site Number 392185
Investigational Site Number 840005
Investigational Site Number 804009
Investigational Site Number 392116
Investigational Site Number 840123
Investigational Site Number 840023
Investigational Site Number 392140
Investigational Site Number 643012
Investigational Site Number 484013
Investigational Site Number 710005
Investigational Site Number 076008
Investigational Site Number 840040
Investigational Site Number 170002
Investigational Site Number 152001
Investigational Site Number 840128
Investigational Site Number 410015
Investigational Site Number 124002
Investigational Site Number 840036
Investigational Site Number 840018
Investigational Site Number 840010
Investigational Site Number 392182
Investigational Site Number 710001
Investigational Site Number 643011
Investigational Site Number 392163
Investigational Site Number 840114
Investigational Site Number 840034
Investigational Site Number 826002
Investigational Site Number 392161
Investigational Site Number 840127
Investigational Site Number 348003
Investigational Site Number 392106
Investigational Site Number 410013
Investigational Site Number 840019
Investigational Site Number 840048
Investigational Site Number 484001
Investigational Site Number 724008
Investigational Site Number 804023
Investigational Site Number 710010
Investigational Site Number 032001
Investigational Site Number 840021
Investigational Site Number 392129
Investigational Site Number 158001
Investigational Site Number 840113
Investigational Site Number 484015
Investigational Site Number 276004
Investigational Site Number 804001
Investigational Site Number 036003
Investigational Site Number 840032
Investigational Site Number 250008
Investigational Site Number 076006
Investigational Site Number 643004
Investigational Site Number 032003
Investigational Site Number 392117
Investigational Site Number 032010
Investigational Site Number 032008
Investigational Site Number 276007
Investigational Site Number 152013
Investigational Site Number 840118
Investigational Site Number 250004
Investigational Site Number 392128
Investigational Site Number 840124
Investigational Site Number 392103
Investigational Site Number 392179
Investigational Site Number 616006
Investigational Site Number 840067
Investigational Site Number 484004
Investigational Site Number 710007
Investigational Site Number 392159
Investigational Site Number 392130
Investigational Site Number 840079
Investigational Site Number 840025
Investigational Site Number 840133
Investigational Site Number 840069
Investigational Site Number 840108
Investigational Site Number 076007


title: MOre REsponse on Cardiac Resynchronization Therapy (CRT) With MultiPoint Pacing (MPP)

acronym: MORE-CRT MPP

summary: The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.

ReferenceCitation: Leclercq C, Burri H, Curnis A, Delnoy PP, Rinaldi CA, Sperzel J, Lee K, Calò L, Vicentini A, Concha JF, Thibault B. Cardiac resynchronization therapy non-responder to responder conversion rate in the more response to cardiac resynchronization therapy with MultiPoint Pacing (MORE-CRT MPP) study: results from Phase I. Eur Heart J. 2019 Sep 14;40(35):2979-2987. doi: 10.1093/eurheartj/ehz109.

name: Université de Rennes I, CICIT 804, Rennes, CHU Pontchaillou, Rennes, France

family: Leclercq

full_name: Christophe Leclercq

given: Christophe

name: University of Geneva, Geneva, Switzerland

family: Burri

full_name: Haran Burri

given: Haran

name: Università degli Studi di Brescia, Brescia, Italy

family: Curnis

full_name: Antonio Curnis

given: Antonio

name: Isala Klinieken, Zwolle, The Netherlands

family: Delnoy

full_name: Peter Paul Delnoy

given: Peter Paul

family: Rinaldi

full_name: Christopher A Rinaldi

given: Christopher A

family: Sperzel

full_name: Johannes Sperzel

given: Johannes

family: Lee

full_name: Kwangdeok Lee

given: Kwangdeok

family: Calò

full_name: Leonardo Calò

given: Leonardo

family: Vicentini

full_name: Alfredo Vicentini

given: Alfredo

name: Hospital Universitario Infanta Cristina, Spain

family: Concha

full_name: Joaquin Fernandez Concha

given: Joaquin Fernandez

name: Université de Montréal, Montreal, Canada

family: Thibault

full_name: Bernard Thibault

given: Bernard

journal_name: European Heart Journal

oa_host_type: publisher

evidence: open (via free pdf)

publisher: Oxford University Press (OUP)

publisher_dissemination: Oxford University Press

publisher_group: Oxford University Press

publisher_normalized: Oxford University Press

ReferenceCitation: Leclercq C, Burri H, Curnis A, Delnoy PP, Rinaldi CA, Sperzel J, Lee K, Cohorn C, Thibault B; MORE-CRT MPP Investigators. Rationale and design of a randomized clinical trial to assess the safety and efficacy of multipoint pacing therapy: MOre REsponse on Cardiac Resynchronization Therapy with MultiPoint Pacing (MORE-CRT MPP-PHASE II). Am Heart J. 2019 Mar;209:1-8. doi: 10.1016/j.ahj.2018.12.004. Epub 2018 Dec 8.

family: Cohorn

full_name: Clay Cohorn

given: Clay

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

title: Rationale and design of a randomized clinical trial to assess the safety and efficacy of multipoint pacing therapy: MOre REsponse on Cardiac Resynchronization Therapy with MultiPoint Pacing (MORE-CRT MPP–PHASE II)

location_country:
Finland
Malaysia
Greece
Australia
Belgium
Denmark
Taiwan
India
France
Poland
Canada
Korea, Republic of
Colombia
Sweden
Saudi Arabia
Switzerland
Netherlands
Malta
Singapore
Puerto Rico
China
Portugal
United States
Germany
United Kingdom
Italy
Austria
Lebanon
Israel
Spain

location_facility: McGill University Health Centre General Hospital

location_facility: Centro Hospitalar do Alto Ave, Unidade de Guimarães

location_facility: Institute Cardio. Paris-Sud - Institut Jacques Cartier

location_facility: Hopital Cantonal Universitaire de Geneva

location_facility: Complexo Hospitalario Universitario de Santiago

location_facility: Herz- und Gefäßzentrum am Krankenhaus Neu-Bethlehem

location_facility: Az. Osp. Universitaria Pisana-Presidio Santa Chiara

location_facility: University of Texas Southwestern Medical Center at Dallas

location_facility: Deutsches Herzzentrum München des Freistaates Bayern

location_facility: Baylor All Saints Medical Center at Fort Worth

location_facility: Escorts Heart Institute and Research Centre

location_facility: St. Elizabeth Medical Center - South Unit

location_facility: Hospital General Universitario Gregorio Maranon

location_facility: Ospedale S. Giovanni Calibita Fatebenefratelli di Roma

location_facility: CHI Health Creighton University Medical Center-Bergan Mercy

location_facility: Cardiology Associates of Fairfield County, PC

location_facility: Manchester Heart Center, Manchester Royal Infirmary

location_facility: Azienda Ospedaliera S. Anna e S Sebastiano

location_facility: Seoul National University Bundang Hospital

location_facility: Szpital Kliniczny Premienienia Panskiego

location_facility: Hospital Universitari i Politecnic La Fe

location_facility: Wojewodzki Specjalistyczny Szpital im. Bieganskiego

location_facility: Azienda Ospedaliera "Civile - Maria Paternò Arezzo"

location_facility: Samaritan Heart & Vascular Institute - Cardiology Dept.

location_facility: Az Osp.Universitaria Maggiore della Carità

location_facility: Gornoslaskie Centrum Medyczne im.prof. Leszka Gieca

location_facility: Universitäts-Herzzentrum Freiburg - Bad Krozingen

location_facility: Centre Hospitalier de Belfort-Montbeliard

location_facility: Universitatsmedizin Berlin - Campus Benjamin Franklin (CBF)

location_facility: Medizinische Einrichtungen der Universität zu Köln

location_facility: American University of Beirut Medical Center

location_facility: Postgraduate Institute of Medical Education & Research

location_facility: Ospedale Civile Maggiore di Verona Borgo Trento

location_facility: Hospital Universitario Virgen de la Nieves